tiprankstipranks
Trending News
More News >

Percheron Therapeutics Retains Board with Strong Shareholder Support

Story Highlights
Percheron Therapeutics Retains Board with Strong Shareholder Support

Don’t Miss TipRanks’ Half Year Sale

Percheron Therapeutics ( (AU:PER) ) has issued an announcement.

Percheron Therapeutics Limited announced the results of its General Meeting, where over 90% of shareholders voted to retain the current Board, rejecting nominees from Powerhouse Ventures Limited. This strong shareholder support allows the company to concentrate on its mission to restore value for shareholders and continue its focus on developing therapies for rare diseases.

More about Percheron Therapeutics

Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for rare diseases. The company’s lead program, avicursen (ATL1102), is an antisense oligonucleotide targeting the CD49d receptor, investigated for inflammatory conditions like multiple sclerosis and Duchenne muscular dystrophy.

Technical Sentiment Signal: Sell

Current Market Cap: $7.6M

For an in-depth examination of PER stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1